Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
22.21
-0.94 (-4.06%)
At close: Nov 7, 2025, 4:00 PM EST
21.80
-0.41 (-1.85%)
After-hours: Nov 7, 2025, 4:31 PM EST
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $9.70M in the quarter ending September 30, 2025, a decrease of -32.03%. This brings the company's revenue in the last twelve months to $55.70M, down -84.07% year-over-year. In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%.
Revenue (ttm)
$55.70M
Revenue Growth
-84.07%
P/S Ratio
39.02
Revenue / Employee
$115,323
Employees
483
Market Cap
2.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BEAM News
- 3 days ago - Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 days ago - Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 16 days ago - Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential - Seeking Alpha
- 2 months ago - Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 2 months ago - Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 2 months ago - Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - GlobeNewsWire
- 3 months ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire